Evidence map›Paper›PMID 36547068›Full record

ArticleCurrent issues in molecular biology2022

Antioxidant Efficacy of Esculetin against Tert-Butyl Hydroperoxide-Induced Oxidative Stress in HEK293 Cells.

Woo Kwon Jung, Su-Bin Park, Hwa Young Yu, Yong Hwan Kim, Junghyun Kim

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Methanolic Extract ofCurrent issues in molecular biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Protective Effects and Mechanisms of Esculetin against HMolecules (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Woo Kwon JungDepartment of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.
Su-Bin ParkDepartment of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.
Hwa Young YuDepartment of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.
Yong Hwan KimDepartment of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.
Junghyun KimDepartment of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.ORCID 0000-0002-9003-2158
Jeonbuk National University · KR

Funding

Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries 1210400202HD020
6 · The paper itself

Abstract

Esculetin is an antioxidant and anti-inflammatory compound derived from coumarin. Oxidative stress can cause overproduction of reactive oxygen species (ROS), which can lead to the development of chronic kidney failure. In this study, human embryonic kidney 293 (HEK293) cells were treated with tert-butyl hydroperoxide (t-BHP) to determine the antioxidant effects of esculetin. HEK293 cells were treated with t-BHP to validate changes in cell viability, ROS production, and apoptosis, and then treated with esculetin to evaluate the changes. Changes in mRNA and protein levels were analyzed using a proteome kit, PCR, and Western blotting. Esculetin improved HEK293 cell viability and reduced apoptosis caused by t-BHP-induced oxidative stress. At the mRNA and protein levels, esculetin decreased pro-apoptotic factor expression as well as increased anti-apoptotic factor expression. The antioxidant efficacy of esculetin was validated when it inhibited the apoptosis caused by t-BHP-induced oxidative stress in HEK293 cells.

Indexed as

esculetinkidney dysfunctionreactive oxygen speciestert-butyl hydroperoxide

Identifiers

PMID36547068
PMCPMC9777115
OpenAlexW4311015417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.